Skip to main content
Fig. 3 | Critical Care

Fig. 3

From: Intravenous methylprednisolone pulse therapy and the risk of in-hospital mortality among acute COVID-19 patients: Nationwide clinical cohort study

Fig. 3

The relative risk of in-hospital mortality according to gap days between the time of intubation of mechanical ventilation and a pulse methylprednisolone use (≥ 500 mg per day) or b intermediate/higher dose of steroid (40–250 mg per day) among COVID-19 patients, using the restricted subset dataset. No-gap day (day 0) was set as reference to compare risk of in-hospital mortality among gap days both in a and b. We analysed 66,418 out of 67,348 patients, since 930 patients received both an intermediate/higher dose of intravenous methylprednisolone and pulse methylprednisolone therapy during the same admission period. The median (interquartile range) pulse methylprednisolone therapy was 1000 (500–1000) mg per day. The median (interquartile range) intermediate/higher dose of intravenous methylprednisolone was 80 (40–250) mg per day

Back to article page

Critical Care

ISSN: 1364-8535